Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Datadog Inc (DDOG) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Datadog IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Datadog Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while Datadog Inc trades at $242.34 (market cap $88.61B). The key difference: Datadog Inc is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Datadog Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYDDOG
Market Cap
$29.60B$88.61B
Sector
HealthTechnology
52-Week High
$491.22$288.15
52-Week Low
$205.48$102.62
Enterprise Value
$27.56B$84.90B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Datadog Inc

Datadog (DDOG) trades at $244.2, down 6.36% over 24 hours, with a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. Revenue grew 36% year-over-year to $1.12 billion, but the stock faces pressure from high valuations (P/E 493.56) and concerns over a major customer's reduced usage. Analyst consensus remains strongly bullish with an 83.34% buy rating and a $288.55 price target, suggesting significant upside potential from current levels.

The outlook is mixed: robust fundamentals and AI-driven growth support long-term value, but near-term volatility persists due to premium valuation and investor skepticism post-earnings. Key risks include customer concentration, competitive pressures, and execution challenges in sustaining high growth rates. Investors should weigh strong analyst conviction against technical weakness and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Datadog Inc

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.

Read more on DDOG